DR-321 Analyzing the correlations between gene expressions and mutations in breast cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-321 Analyzing the correlations between gene expressions and mutations in breast cancer
Combination of several markers is necessary to effectively detect and diagnose cancer. To look for such fingerprints high-throughput multi-omics data …
DR-317 Integrated analysis of RNASeq and WGS data to target cancer with precision AI
The genomic mutational landscape observed in cancer cells represents impaired biological mechanisms, especially associated with replication stress response (RSR). Some …
DR-339 Analysis of the break rate profiles of metastatic solid tumours to investigate genomic enrichment of structural variants
We recently developed statistical framework, named Katdetectr, that robustly detects clustered somatic mutations (kataegis) in the DNA from cancer cells. …
DR-343 Chromosomal instability signatures and metastasis
Different factors can alter the DNA in a tumour cell such as chemical agents or the inability of the cells …
DR-283 The genetic basis of disease progression and drug resistance in advanced metastatic cancer
Metastasis is the primary cause of death in cancer and the mechanisms of cancer progression and metastasis are varied and …
DR-330 Enhancers driving oncogenes in ovarian cancer
Ovarian cancer is the most lethal gynecological cancer in the western world. It is typically diagnosed at a late stage …
DR-323 clusterCUP
Tumors are classified mainly by their cell of origin. Large cell neuroendocrine carcinomas are rare lung tumors and clinical studies …
DR-327 Copy number features as a novel biomarker of homologous recombination (HR) status in HR deficient (HRD) tumors
Homologous recombination deficiency (HRD) is one of the driving factors of tumorigenesis as leads to damage in the repair process …
DR-328 Intratumoral microbiome characterisation to predict patient outcome in the context of immune-checkpoint inhibitors
Immune-checkpoint inhibitors are changing the treatment options for primary and metastatic tumor cancer patients. However, heterogeneity of response is observed …
DR-326 Cancer evolutionary dynamics
Cancers change over time. Understanding how cancers change is important for determining a patient’s prognosis and to improve the effectiveness …
DR-264 Genetic variation in the outcome of cancer
There were 18.1 million new cancer patients worldwide in 2020. Of these patients, some will recover after treatment while the …
DR-309 Unraveling the mystery of early-onset colorectal cancer
The incidence of early-onset colorectal cancer (eoCRC) in patients < 50 years of age is rapidly increasing. Despite indications that …
Er komen steeds meer oncologische geneesmiddelen beschikbaar die maar voor een klein deel van de patiënten geschikt zijn. Op dit moment vinden we die patiënten niet. Bij élke patiënt met uitgezaaide kanker zou uitgebreide genetische screening moeten plaatsvinden.